Vaccine maker BioNTech has forecast a worse than expected slump in revenues this year as demand for coronavirus immunisation wanes, underlining the scale of the challenge facing companies that enjoyed windfalls from the pandemic.
疫苗制造商BioNTech預計，隨著對冠狀病毒免疫的需求減弱，該公司今年的營收將出現比預期更嚴重的下滑，這突顯出從疫情中大賺一筆的公司所面臨的挑戰之大。
您已閱讀7%（306字），剩余93%（3937字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。